Mark A Dombroski

US Patent:

6433009, Aug 13, 2002

Filed:

Oct 31, 2000

Appl. No.:

09/703142

Inventors:

Mark Anthony Dombroski - Waterford CT
James Frederick Eggler - Stonington CT

Assignee:

Pfizer Inc - New York NY

International Classification:

A61K 3134

US Classification:

514471, 514445, 514592, 549 65, 549478, 564 42

Abstract:

A compound of the formula wherein R and R are as defined above, useful in the treatment and condition selected from the group consisting of meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation, tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzheimers disease, percussion injury, depression, atherosclerosis, osteoporosis in a mammal, including a human.

US Patent:

6461822, Oct 8, 2002

Filed:

Aug 31, 1999

Appl. No.:

09/387372

Inventors:

Christopher A. Gabel - Ledyard CT
Richard J. Griffiths - East Lyme CT
James F. Eggler - Stonington CT
Mark A. Dombroski - Waterford CT
Kieran Geoghegan - Mystic CT

Assignee:

Pfizer Inc. - New York NY

International Classification:

G01N 3353

US Classification:

435 72, 435 71, 530350, 536 235, 564305

Abstract:

The present invention relates to the identification of diarylsulfonylurea binding proteins (DBPs) as therapeutic targets for agents that suppress the release of inflammatory mediators such as interleukin IL-1 and IL-1.

US Patent:

6664395, Dec 16, 2003

Filed:

Apr 4, 2002

Appl. No.:

10/115952

Inventors:

Michael A. Letavic - Mystic CT
Mark A. Dombroski - Waterford CT
Kim F. McClure - Mystic CT
Ellen R. Laird - Longmont CT

Assignee:

Pfizer Inc - New York NY

International Classification:

C07D40304

US Classification:

544405, 5462741, 548181, 548206, 548235, 548247, 548257, 548260, 548261, 51425505, 514338, 514359, 514365, 514372, 514374, 514378, 514396, 514406, 514422

Abstract:

The present invention relates to novel benzotriazoles of the formula I wherein Het is an optionally substituted 5-membered heterocycle containing one to two heteroatoms selected from nitrogen, sulfur and oxygen wherein at least one of said heteroatoms atoms must be nitrogen; R is selected from the group consisting of hydrogen, (C -C )alkyl or other suitable substituents; R is selected from the group consisting of hydrogen, (C -C )alkyl or other suitable substituents; s is an integer from 0-5; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

US Patent:

6696464, Feb 24, 2004

Filed:

Mar 11, 2002

Appl. No.:

10/094760

Inventors:

Kim F. McClure - Mystic CT
Michael A. Letavic - Mystic CT
Mark A. Dombroski - Waterford CT
Allen J. Duplantier - Ledyard CT
Ellen R. Laird - Longmont CO

Assignee:

Pfizer Inc - New York NY

International Classification:

A61K 3144

US Classification:

514303, 546119

Abstract:

The present invention relates to novel triazolo-pyridines of the formula I wherein Het is an optionally substituted 5-membered heterocycle containing one to two heteroatoms selected from nitrogen, sulfur and oxygen wherein at least one of said heteroatoms atoms must be nitrogen; R is selected from the group consisting of hydrogen, (C -C )alkyl or other suitable substituents; R is selected from the group consisting of hydrogen, (C -C )alkyl or other suitable substituents; s is an integer from 0-5; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

US Patent:

6974812, Dec 13, 2005

Filed:

Dec 30, 2003

Appl. No.:

10/748340

Inventors:

Mark A Dombroski - Waterford CT, US
Allen J. Duplantier - Ledyard CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D253/075
C07D295/02
A61K031/53
A61K031/5377
A61P019/02

US Classification:

514242, 5142315, 544182, 544112

Abstract:

The present invention provides benzamide inhibitors of the P2Xreceptor of the formula: wherein R-Rare as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

US Patent:

7005523, Feb 28, 2006

Filed:

Aug 27, 2003

Appl. No.:

10/649216

Inventors:

Mark A. Dombroski - Waterford CT, US
Michael A. Letavic - Mystic CT, US
Kim F. McClure - Mystic CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 471/02
A61K 31/44

US Classification:

546119, 514303

Abstract:

The present invention relates to novel cycloalkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

US Patent:

7012143, Mar 14, 2006

Filed:

Aug 27, 2003

Appl. No.:

10/649255

Inventors:

Mark A. Dombroski - Waterford CT, US
Michael A. Letavic - Mystic CT, US
Kim F. McClure - Mystic CT, US

International Classification:

C07D 47/02
A61K 31/44

US Classification:

546118, 514303

Abstract:

The present invention relates to novel cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

US Patent:

7037923, May 2, 2006

Filed:

Aug 27, 2003

Appl. No.:

10/649265

Inventors:

Mark A. Dombroski - Waterford CT, US
Michael A. Letavic - Mystic CT, US
Kim F. McClure - Mystic CT, US

Assignee:

Pfizer, Inc. - New York NY

International Classification:

A61K 31/44
C07D 471/02

US Classification:

514303, 546119

Abstract:

The present invention relates to novel alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates and methods for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.